Stocksigma LogoStocksigma Logo

Anupam Rasayan Concludes Acquisition of 48.2% Controlling Stake in Bliss GVS Pharma

Anupam Rasayan completed the acquisition of a 48.2% controlling stake in Bliss GVS Pharma at ₹299 per share (~24x LTM earnings) via subsidiary Mates Visa

Anupam Rasayan Concludes Acquisition of 48.2% Controlling Stake in Bliss GVS Pharma

Anupam Rasayan India Ltd · Press Release · 29 Sept 2026, 1:23 am

Anupam Rasayan Concludes Acquisition of 48.2% Controlling Stake in Bliss GVS Pharma Anupam Rasayan completed the acquisition of a 48.2% controlling stake in Bliss GVS Pharma at ₹299 per share (~24x LTM earnings) via subsidiary Mates Visa Consultancy on 28th Sep'26. The deal was funded via a ₹300 crore term loan and ~₹1,450 crore raised through non-controlling instruments from investors led by Bain Capital. This expands Anupam Rasayan into finished dosage formulations. Post-consolidation of Anupam Rasayan, Tanfac, Jayhawk, and Bliss GVS, the combined platform expects pro-forma revenue of >₹4,000 crore and EBITDA of ~₹834 crore.

Original exchange filing (PDF)

More announcements from Anupam Rasayan India Ltd

All Anupam Rasayan India Ltd announcements